Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Total Current Liabilities: 2009-2025

Historic Total Current Liabilities for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to $87.9 million.

  • Northwest Biotherapeutics' Total Current Liabilities rose 47.58% to $87.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.9 million, marking a year-over-year increase of 47.58%. This contributed to the annual value of $68.3 million for FY2024, which is 51.04% up from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Total Current Liabilities stood at $87.9 million, which was up 4.75% from $83.9 million recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Total Current Liabilities peaked at $363.4 million during Q1 2021, and registered a low of $39.9 million during Q2 2023.
  • Over the past 3 years, Northwest Biotherapeutics' median Total Current Liabilities value was $59.6 million (recorded in 2024), while the average stood at $62.3 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first soared by 816.33% in 2021, then plummeted by 72.79% in 2022.
  • Over the past 5 years, Northwest Biotherapeutics' Total Current Liabilities (Quarterly) stood at $133.8 million in 2021, then dropped by 5.80% to $126.0 million in 2022, then slumped by 64.13% to $45.2 million in 2023, then spiked by 51.04% to $68.3 million in 2024, then surged by 47.58% to $87.9 million in 2025.
  • Its Total Current Liabilities stands at $87.9 million for Q3 2025, versus $83.9 million for Q2 2025 and $83.1 million for Q1 2025.